Changes in the composition of the human fecal microbiome following bacteriotherapy for recurrent Clostridium difficile-associated diarrhea

Changes in the Composition of the Human Fecal Microbiome Following Bacteriotherapy for Recurrent Clostridium difficile-Associated Diarrhea Alexander Khoruts, MD 1† , Johan Dicksved, PhD 2† , Janet K. Jansson, PhD 3 , and Michael J. Sadowsky, PhD 4* Department of Medicine, and Center for Immunology, University of Minnesota, Minneapolis, MN, 2 Department of Microbiology, Swedish University of Agricultural Sciences, Uppsala, Sweden, 3 Lawrence Berkeley National Laboratory, Division of Earth Sciences, Berkeley, CA, and 2 Department of Soil, Water, and Climate; BioTechnology Institute; and Microbial and Plant Genomics Institute, University of Minnesota, St. Paul, MN. *Corresponding Author Contact Information: Michael J. Sadowsky, University of Minnesota, BioTechnology Institute, and Department of Soil, Water, and Climate, 1991 Upper Buford Circle, 439 Borlaug Hall, St. Paul, MN 55108; Phone (612) 624-2706; email: Sadowsky@umn.edu Alexander Khoruts and Johan Dicksved contributed equally to this study. ACKNOWLEDGEMENTS We would like to thank Misha Mehta for help with the phylogenetic analyses. We also thank Lisa Gallagher and Heidi Myers for nursing assistance in performance of bacteriotherapy. This research was supported, in part, by U. S. Department of Energy Contract DE-AC02-05CH11231 with Lawrence Berkeley National Laboratory to JKK and by funding from the University of Minnesota Agricultural Experiment Station to MJS. ABSTRACT

[1]  D. Gordon,et al.  Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. , 1985, The American journal of gastroenterology.

[2]  J. Jansson,et al.  Monitoring of Antibiotic-Induced Alterations in the Human Intestinal Microflora and Detection of Probiotic Strains by Use of Terminal Restriction Fragment Length Polymorphism , 2005, Applied and Environmental Microbiology.

[3]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[4]  B. Aronsson,et al.  Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. , 1984, Scandinavian journal of infectious diseases.

[5]  J. Bakken,et al.  Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Blöcker,et al.  Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. , 1989, Nucleic acids research.

[7]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[8]  D. Fone,et al.  Proton pump inhibitor therapy is a risk factor for Clostridium difficile‐associated diarrhoea , 2006, Alimentary pharmacology & therapeutics.

[9]  G. Pershagen,et al.  Molecular Fingerprinting of the Fecal Microbiota of Children Raised According to Different Lifestyles , 2007, Applied and Environmental Microbiology.

[10]  W. Roediger.  The starved colon—Diminished mucosal nutrition, diminished absorption, and colitis , 1990, Diseases of the colon and rectum.

[11]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[12]  S. Finegold,et al.  Bacterial interference between Clostridium difficile and normal fecal flora. , 1981, The Journal of infectious diseases.

[13]  K. Wilson.  The microecology of Clostridium difficile. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Jansson,et al.  Community Structure of Actively Growing Bacterial Populations in Plant Pathogen Suppressive Soil , 2007, Microbial Ecology.

[15]  J. Rask-Madsen,et al.  BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.

[16]  L. Brandt,et al.  Treatment of recurrent Clostridium difficile–associated diarrhea by administration of donated stool directly through a colonoscope , 2000, American Journal of Gastroenterology.

[17]  J. Jansson,et al.  Molecular analysis of the gut microbiota of identical twins with Crohn's disease , 2008, The ISME Journal.

[18]  B. Wren,et al.  Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. , 2008, Journal of medical microbiology.

[19]  D. Antonopoulos,et al.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. , 2008, The Journal of infectious diseases.

[20]  J. Barkin.  Impact of Clostridium difficile on Inflammatory Bowel Disease , 2008 .

[21]  J. Stein,et al.  Rationale for the luminal provision of butyrate in intestinal diseases , 2000, European journal of nutrition.

[22]  A. Uitterlinden,et al.  Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA , 1993, Applied and environmental microbiology.

[23]  Daniel B. DiGiulio,et al.  Development of the Human Infant Intestinal Microbiota , 2007, PLoS biology.

[24]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[25]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[26]  P. Mastrantonio,et al.  Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. , 2004, Journal of medical microbiology.

[27]  Les Dethlefsen,et al.  The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing , 2008, PLoS biology.

[28]  P. Lawson,et al.  Anaerostipes caccae gen. nov., sp. nov., a new saccharolytic, acetate-utilising, butyrate-producing bacterium from human faeces. , 2002, Systematic and applied microbiology.

[29]  R. Ley,et al.  Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine , 2006, Cell.

[30]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[31]  Kimberly A. Reske,et al.  Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  A. Ananthakrishnan,et al.  Clostridium difficile and inflammatory bowel disease. , 2010, The Medical clinics of North America.

[33]  A. Berstad,et al.  Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. , 1998, Scandinavian journal of gastroenterology.

[34]  C. Cicogna,et al.  Past, Present, and Future Therapies for Clostridium difficile–Associated Disease , 2006, The Annals of pharmacotherapy.

[35]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[36]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.